Moseley H, Ibbotson S, Woods J, Brancaleon L, Lesar A, Goodman C, Ferguson J
The Photobiology Unit & Scottish PDT Centre, University of Dundee, Ninewells Hospital & Medical School, Dundee DD1 9SY, Scotland, United Kingdom.
Lasers Surg Med. 2006 Jun;38(5):403-16. doi: 10.1002/lsm.20369.
The Scottish PDT Centre has carried out 3,442 treatments on 762 patients with superficial skin lesions, especially superficial basal cell carcinoma (sBCC), Bowen's disease (BD) and actinic keratosis (AK). STUDY DESIGN MATERIALS AND METHODS: The article reviews our experience of various light sources and associated dosimetry; thereafter we discuss clinical outcome followed by some of our research studies in clinically important areas.
We show that improved dosimetry is required to ensure an optimal light dose is delivered to the tumour. We have shown that photosensitizers and proteins interact in such a way that their photophysical and photochemical properties are modified. We have also demonstrated the presence of DNA strand breaks with two different photosensitizers, but there is no evidence that PDT is significantly mutagenic in clinical practice.
In our experience, topical PDT is generally well tolerated and is an effective treatment of sBCC, BD, AK, field change and lesions at sites of poor healing.
苏格兰光动力治疗中心已对762例患有浅表皮肤病变的患者进行了3442次治疗，这些病变主要为浅表基底细胞癌（sBCC）、鲍恩病（BD）和光化性角化病（AK）。
研究设计、材料与方法：本文回顾了我们在各种光源及相关剂量测定方面的经验；随后我们讨论了临床结果，接着介绍了我们在一些重要临床领域的研究。
我们表明，需要改进剂量测定以确保向肿瘤输送最佳光剂量。我们已经证明，光敏剂与蛋白质相互作用的方式会改变它们的光物理和光化学性质。我们还证明了两种不同光敏剂会导致DNA链断裂，但没有证据表明光动力治疗在临床实践中具有显著致突变性。
根据我们的经验，局部光动力治疗一般耐受性良好，是治疗sBCC、BD、AK、场效应改变及愈合不良部位病变的有效方法。
